Supplementary files for 'BRAF inhibition and the spectrum of granulomatous reactions: A review', in publication by the Journal of the American Academy of Dermatology.
Focal amplifications (FAs) resulting in copy number gain of targeted genomic regions can mediate targeted therapy resistance. Understanding the structure, plasticity and vulnerability of FAs is critic
The therapeutic benefit of approved BRAF and MEK inhibitors (BRAFi/MEKi) in patients with brain metastatic BRAF V600E/K-mutated melanoma is limited and transient. Resistance largely occurs through the
Human melanoma samples were collected pre, on, and progression on BRAF inhibitor therapy. RNA was extracted and run on RNA-seq. This has provided insights into different categories of BRAF inhibitor r
In this report, we generated eight matched pairs of vemurafenib sensitive/resistant melanoma lines and subjected these to concurrent RNA-seq and H3K27Ac ChIP-seq analysis. Globally, we identified two
